

MUCOEPIDERMOID CARCINOMA OF THE SALIVARY GLANDS. A RETROSPECTIVE STUDY OF 51 CASES AND REVIEW OF THE LITERATURE

Janet O. Guevara-Canales¹, Rafael Morales-Vadillo¹,
Guillermo Guzmán-Arias¹, Carlos E. Cava-Vergíu¹,
Henry Guerra-Miller², Jaime E. Montes-Gil²

¹ Universidad de San Martín de Porres (USMP), Facultad de Odontología,
Instituto de Investigación, Lima, Perú.

² National Institute for Neoplastic Diseases, Lima, Peru.

ABSTRACT

The aim of this study is to present the casuistic of mucoepidermoid carcinoma of salivary glands in patients diagnosed at "Dr. Eduardo Cáceres Graziani" National Institute for Neoplastic Diseases, Lima, Perú.

From January 2002 to December 2012, 51 cases were diagnosed as mucoepidermoid carcinoma. The number of female patients was higher, with 28 cases (54.9%), and regarding age distribution, 33.3% of the patients were under 30 years old. Pain was one of the main symptoms, and

74.5% of the mucoepidermoid carcinomas were located in the parotid gland.

It is concluded that epidemiology regarding age and gender of the 51 cases analyzed was in the same range as other studies, and that most cases were located in major salivary glands, in agreement with reports on other populations. Other characteristics showed a homogeneous distribution.

Key words: Salivary gland neoplasms; mucoepidermoid tumor; epidemiology, neoplasms.

CARCINOMA MUCOEPIDERMÓIDE DE GLÁNDULAS SALIVALES. ESTUDIO RETROSPECTIVO DE 51 CASOS Y REVISIÓN DE LA LITERATURA

RESUMEN

El propósito de este estudio es presentar la casuística del carcinoma mucoepidermoide de glándulas salivales de pacientes diagnosticados en el Instituto Nacional de Enfermedades Neoplásicas "Dr. Eduardo Cáceres Graziani" Lima, Perú, desde el 2002 hasta el 2012.

Realizamos un estudio retrospectivo en el cual fueron incluidos sujetos con diagnóstico primario de carcinoma mucoepidermoide en glándulas salivales. Entre enero de 2002 y diciembre de 2012, se registraron 51 casos. El número de pacientes de sexo femenino fue mayor, con 28 casos (54,9%) y con respecto a la distribución por edades, el 33,3% de los pacientes eran menores de 30 años de edad. El dolor fue uno de los síntomas principales. El 74,5%

de los carcinomas mucoepidermoides se localizaron en la glándula parótida.

De los hallazgos obtenidos se concluye principalmente que en lo que respecta a la distribución epidemiológica de edad y género de los 51 casos analizados estas variaron en el mismo rango de otros estudios. También se distingue que el mayor número de casos estuvieron localizados en glándulas salivales mayores, dato en concordancia con otras poblaciones reportadas. Las demás características presentaron una distribución homogénea.

Palabras clave: Neoplasias de las glándulas salivales; carcinoma mucoepidermoide; epidemiología; neoplasias.

INTRODUCTION

Neoplasms of the major and minor salivary glands are a challenge for clinicians and histopathologists because they are infrequent and have a wide range of histological, clinical, epidemiological and developmental characteristics¹.

In salivary glands, the most frequent benign tumor is pleomorphic adenoma and the most frequent

malignant tumor is mucoepidermoid carcinoma (MC), according to the Armed Forces Institute of Pathology (AFIP) in Washington².

MC is defined as a malignant epithelial neoplasm of the salivary glands caused by proliferation of secretory cells, formed by a variable proportion of mucous, epidermoid, intermediate, columnar and clear cells, often with a cystic component. Its

biological behavior is related to the histologic tumor grade (low, intermediate or high)²⁻⁴.

MC was studied, described and reported for the first time by Stewart, Foote and Becker in 1945 with regard to tumors with double metaplasia or double constitution, epidermoid cells and mucous producing cells⁵.

Etiology

Little is known regarding the etiological agents of salivary gland neoplasms. Apparently, low-dose radiotherapy used in benign disorders such as acne or obstructive lesions of the lymphoid tissue in the oral cavity or nasopharynx is the main factor involved in the genesis of these tumors. They have not been associated to radiotherapy for the treatment of malignant neoplasms, suggesting that irradiation at high doses is a lower risk factor than irradiation at low doses. Local trauma has also been implicated in the genesis of MC in minor salivary glands⁶.

Epidemiology

Neoplasms of the salivary glands are rare, accounting for less than 2%⁷ of all human neoplasms and about 3% of head and neck tumors^{7,8}. Malignant tumors of the salivary glands are infrequent and account for about 3% of all malignant neoplasms of head and neck⁸.

Malignant neoplasms originating in minor salivary glands are less than 25% of all salivary neoplasms^{9,10},

and most of the tumors arising in minor salivary glands are malignant^{9,11}.

MC is the most common malignant neoplasm in major and minor salivary glands¹², accounting for nearly 30% of all malignant neoplasms of the salivary glands. Approximately half the MCs occur in the major salivary glands, with 80% in the parotid gland, 8 to 13% in the submaxillary gland and 2 to 4% in the sublingual gland¹³. Central mucoepidermoid tumors located in the jaws are a recognized entity. Browand and Waldron reported 9 cases and examined the 41 previously published cases¹⁴.

Some authors report that MC is evenly distributed between sexes¹⁵, but most authors report that glandular MC is more frequent in females, with a female:male ratio of 2:1^{6,16} or 3:2^{17,18}.

The onset occurs between the 2nd and 8th decades of life, and it is the most frequent malignant tumor in persons under 20 year of age, in whom there is a predilection for the hard palate. There is also clear predilection for white race^{6,16}.

Clinical manifestation

Between 70% and 80% of neoplasms in general of the salivary glands are located in the parotid, while the palate is the most common site for neoplasms of minor salivary glands². Similarly, just over 70% of MCs are located in major glands, with the parotid being the most frequent site¹⁹, (with almost half the cases) (Fig. 1 and 2), followed by the submandibular gland and sublingual gland³. MCs represent 23% of

Fig. 1: Female patient, 30 years old. Tumorous lesion in left parotid gland. Patient complained of pain and paresthesia. One year of illness with slow, progressive growth. Diagnosed with high-grade MC and died six months later, after radiation treatment.



Fig. 2: Male patient, 48 years old. Tumorous lesion in left parotid gland. Patient complained of paresthesia. Diagnosed with high grade MC. Seventeen months after surgery and radiotherapy, presented pulmonary metastasis and died 5 months later.



all tumors in the minor salivary glands²⁰, with the palate being the most commonly affected site (with almost half the cases in hard palate, the second most frequent location after parotid gland), and they are found less frequently in other minor salivary glands such as those of the tongue, floor of the mouth, gum, lips and cheek mucosa, the ectopic salivary tissue being another location, though exceptional.

Clinically, in major glands, MCs appear as solitary, asymptomatic enlargements of the parotid body or pole, or of the submaxillary region⁸. In minor glands they appear as blue or purplish-red fluctuating masses with a smooth surface, and are often clinically mistaken for mucoceles²¹.

The average latency period is one year, but may vary widely. MCs sometimes grow rapidly after a period of quiescence. In high-grade lesions there is onset of pain, facial paralysis and fixation in neighboring structures⁸.

Discovery in minor glands is sometimes accidental during a routine mouth exploration. Rapidly growing tumors are very unusual. The surface is usually smooth, but if it is ulcerated, it is usually associated to more aggressive forms. If it is located at the base of the tongue it may cause dysphagia, while if it affects the bone it may cause insensitivity in teeth⁶.

Histology

According to the bicellular theory, salivary gland tumors are formed by²²:

- a) Duct luminal cells and/or acinar cells plus myoepithelial cells,
- b) Duct luminal cells or acinar cells, or
- c) Myoepithelial cells only.

Histopathology thus identifies mucosecretory, epidermoid, intermediate^{8,17,18,21}, columnar or clear cells, proliferating alone or in different combinations, in a cystic or solid pattern^{8,21}.

In addition to this cell pattern, there is extracellular matrix produced by the neoplastic myoepithelial cells, collagen, elastic fibers, glycoproteins, glycosaminoglycans and proteoglycans²³.

The anatomical pathology shows they are partially encapsulated, with full encapsulation being very rare^{8,21}.

Most authors consider three grades of differentiation^{8,21} depending on intracystic component, neural invasion, necrosis, mitotic activity and

pleomorphism²⁴. The histological grade in this study was classified following AFIP²⁵, published in the World Health Organization Classification of tumours²⁶ and shown in Table 1 and Figs. 3, 4 and 5.

Diagnosis

The differential diagnoses considered are: necrotizing sialometaplasia (of the palate), mucocele, inverted papilloma or cystadenoma, cystadenocarcinoma, primary or metastatic epidermoid carcinoma, and low-grade polymorphic adenocarcinoma¹⁷.

The most useful and popular techniques for evaluating neoplasms of the salivary glands are currently Computerized Axial Tomography (CAT) and biopsy by needle aspiration. The latter, however, should be taken with precaution because its diagnostic precision is 60-80%, sometimes requiring a repetition of the aspiration or surgical biopsy. The histological information from the biopsy and delimitation of the lesion provided by CAT enable appropriate medical and surgical management²⁷.

Treatment

The treatment depends on the location, clinical aspect and histopathological grade. Low-grade MC is generally treated with surgery only, while high-grade tumors also require radiation and dissection of neck lymph nodes²⁸. The management of intermediate-grade tumors is controversial, perhaps reflecting the controversy in tumor classification²⁹. For tumors in accessory salivary glands, surgical excision is recommended, leaving 1-2 cm safety margins around the tumor⁸.

For treatment of tumors in major glands, gland exeresis is recommended (superficial or deep parotidectomy, submaxilectomy)⁸.

Cervical lymph nodes are removed when lymph nodes are clinically affected (higher incidence of lymph node metastasis in submaxillary location)⁸.

Radiotherapy after surgical treatment with tumor-free margins does not increase local control, as it does in advanced cases, cases with infiltrated resection margins and cases located at the base of the tongue³⁰. Response to chemotherapy is low (best results have been achieved with methotrexate y cisplatin)³¹.

Standard treatment for the main types of salivary gland cancer is surgical resection with adjuvant radiation to reduce failure rates³²⁻³⁴ and even though




Fig. 3: MC, low grade. Histological image showing cystic structures lined with mucinous, squamous and intermediate cells with slightly atypical nuclei and low mitotic activity. Adjacent connective tissue without perineural invasion (H&E Orig. Mag. 100x).




Fig. 4: MC, intermediate grade. Histological image showing tumor with small cystic structures, predominance of intermediate cells, with mucosecretory and epidermoid cells (H&E Orig. Mag. 100x).




Fig. 5: MC, high grade. Histological image showing proliferations of solid islands of epidermoid and intermediate cells with few mucinous cells, with atypical nuclei and greater mitotic activity (H&E Orig. Mag. 100x).

Table 1: Histopathologic features used in grading MC. World Health Organization²⁶.

Histopathologic feature	Point value
Intracystic component <20%	2
Neural invasion	2
Mitosis ($\geq 4/10$ HPFs*)	3
Necrosis	3
Anaplasia	4
Tumor grade	Point score
Low grade	0 - 4
Intermediate grade	5 - 6
High grade	≥ 7

*HPF, High-Power Fields

the role of adjuvant chemotherapy has not been proven, it has been used to treat distant metastasis and non-excisable disease, and to reduce the effects of local/regional recurrence³⁵.

Adjuvant radiotherapy has been shown to have an advantage in survival of patients with tumors larger than 4 cm, but little benefit for patients with small tumors, suggesting that, together with the margins involved, tumors larger than 4 cm are an absolute indication for post-surgical radiotherapy^{32,36-38}.

Further progress in therapy is needed to improve the outcomes of histologic high-grade disease³⁹.

Prognosis

Prognosis depends on clinical stage⁴⁰, (related to anatomical location^{41,42}), histologic grade (patients with low or intermediate-grade tumors have local control and favorable survival rates³⁹) and treatment⁴⁰. Variable prognostic factors have also been reported, such as neural invasion, vascular invasion, and local or distant metastasis, which are associated to clinical outcome for patients²⁵.

Other authors mention the same factors that influence survival, such as histologic grade, clinical stage, paralysis of facial nerve and lymph node

metastasis, in addition to location (worse prognosis in submaxillary), age and sex (better prognosis in young people and females). Mucoepidermoid tumor is one of the few tumors of salivary glands in which flow cytometry has high prognostic value, with greater survival in patients with diploid DNA patterns⁶.

Regarding histologic grade, it has been reported that at the same histopathological grade, tumors in the parotid gland have better prognosis than tumors in the submandibular gland⁴³. Prognosis is better for low-grade lesions and for high-grade lesions when they are in stage I or II^{32,36,37,44}. MC prognosis appears to depend largely on tumor grade, with reports of 5-year MC survival rates of 92%-100% for low grade, 62-92% for intermediate grade and 0-43% for high grade tumors²⁵. MCs with high grade malignancy have a 50% probability of presenting metastasis¹⁷.

Some molecular factors of malignant cells also influence survival rate, e.g. p27, which is a highly favorable prognostic factor for MC, whereas Ki67 is not identified as a survival indicator⁴⁵.

Even with complete resection, there is still a substantial risk of local recurrence (16%-27%) and distant metastasis (13%-26%)^{46,47}.

The aim of this study is to present the epidemiology of salivary gland MC through the casuistic in patients diagnosed at the "Dr. Eduardo Cáceres Graziani" National Institute for Neoplastic Diseases from 2002 to 2012.

MATERIALS AND METHODS

This is an observational, descriptive, cross-sectional, retrospective study which included subjects with primary diagnosis of mucoepidermoid carcinoma of the salivary glands diagnosed at "Dr. Eduardo Cáceres Graziani" National Institute for Neoplastic Diseases, Lima, Peru, from January 2002 to December 2012. Clinical records with incomplete data were excluded.

The study was approved by the institutional review board (protocol: INEN 13:27) and conducted in accordance with the World Medical Association Declaration of Helsinki on medical research protocols and ethics.

The collected data were transferred to a Microsoft Excel program, on which the table was prepared.

The analysis was performed using Windows XP® Operative System (Washington, USA), with the assistance of the statistical program SPSS

(Statistical Package for Social Sciences) version 20.0 for Windows (SPSS, Chicago, IL, USA).

All values found in the different statistical tests were considered with a significance level of 0.05 ($p < 0.05$).

RESULTS

Between January 2002 to December 2012, 349 new cases were found of malignant tumors in salivary glands, of which 4.61% (51) cases were mucoepidermoid carcinoma.

All cases were diagnosed by pathological anatomy studies.

Table 2 shows the distribution of the different characteristics evaluated according to sex. There are more female patients (28 cases; 54.9%; female:male ratio 1.2:1). Age range was 12 to 88 years, with 64.71% of patients aged 60 years or less. In most cases (62.75%), tumor size was smaller or equal to 4 cm at the time of the first visit, and the most frequent location was parotid gland (74.51%). No significant difference was found for these characteristics. Among the signs and symptoms evaluated, the presence of paresthesia was statistically significant ($p = 0.038$). Considering the TNM (T: primary tumor, N: cervical nodules, and M: distant metastasis) staging system for salivary gland carcinoma, cases were most frequently stage T2 (43.14%), which are tumors measuring 2-4 cm with no macroscopic extracapsular extension, N0 (86.27%), which are lesions without metastasis in regional nodules and M0 (68.63%), which is when there are tumors without distant metastasis. With regard to clinical stage, the largest number of cases was in clinical stage IV C (31.37%), followed by clinical stage II (29.41%). Regarding histological grade, cases were distributed evenly between low and high grade, with 39.22% each, and regarding treatment, surgery combined with radiotherapy was the treatment of choice, with 42.18% of the cases.

DISCUSSION

Most epidemiological studies of MC have found females to be affected more frequently than males, e.g. Goode *et al.* studied 234 MC of the major salivary glands, finding that females accounted for 51.3%⁴³. In our study, females accounted for 54.9%, a value similar to those reported by Villavicencio *et al.*⁴⁸ and Schwarz *et al.*⁴⁹. Some authors report a 3:2 female:male ratio^{16,18}, and McHugh *et al.* report a

Table 2: Clinical pathological features of subjects with MC of the salivary glands.

	Clinical characteristics		Female		Male		p Value
			n	%	n	%	
Age (months)	Average		43.107		49.04		0.268
	Minimum		18		12		
	Maximum		79		88		
	Up to 60 years		20	60.6	13	39.4	
	Over 60 years		8	44.4	10	55.6	
Size (cm)	Average		4.25	3.56	5.17	2.96	0.157
	Minimum		1.5		1		
	Maximum		20		12		
	Up to 4 cm		20	62.5	12	37.5	
	Over 4 cm		8	42.1	11	57.9	
Location	Parotid gland		18	47.4	20	52.6	0.165
	Submaxillary gland		5	71.4	2	28.6	
	Minor glands		5	83.3	1	16.7	
Signs	Ulcer	No	24	57.1	18	42.9	0.487
		Yes	4	44.4	5	55.6	
	Pain	No	17	54.8	14	45.2	0.991
		Yes	11	55.0	9	45.0	
	Paresthesia	No	25	62.5	15	37.5	0.038*
		Yes	3	27.3	8	72.7	
	Dysphagia	No	27	56.3	21	43.7	0.439
		Yes	1	33.3	2	66.7	
	Trismus	No	27	54.0	23	46.0	0.360
		Yes	1	100	0	00.0	
TNM (T)	T1		7	70.0	3	30.0	0.235
	T2		13	59.1	9	40.9	
	T3		6	50.0	6	50.0	
	T4A		1	16.7	5	83.3	
	T4B		1	100	0	00.0	
TNM (N)	N0		25	56.8	19	43.2	0.224
	N1		3	75.0	1	25.0	
	N2A		0	00.0	2	100	
	N2B		0	00.0	1	100	
TNM (M)	M0		20	57.1	15	42.9	0.634
	M1		8	50.0	8	50.0	
Clinical stage	I		4	66.7	2	33.3	0.051
	II		9	60.0	6	40.0	
	III		4	57.1	3	42.9	
	IV A		1	50.0	1	50.0	
	IV B		2	40.0	3	60.0	
	IV C		8	50.0	8	50.0	
Histological grade	Low grade		14	70.0	6	30.0	0.068
	Intermediate grade		7	63.3	4	36.4	
	High grade		7	35.0	13	65.0	
Treatment	Sg		10	66.7	5	33.3	0.504
	Sg + Rt		10	47.6	11	52.4	
	Sg + Rt + Cht		0	0.0	1	100	
	Rt + Cht		1	100	0	0.0	
	Rt		7	53.8	6	46.2	

* Statistically significant value

TNM: Classification of Malignant Salivary Gland Tumor Stages.

Cht Chemotherapy; Rt Radiotherapy; Sg Surgery.

1:1.2 male:female ratio³⁹. Another recent study is consistent with the above, finding 67% of the cases in females²⁹.

MC is the most common malignant neoplasm of the salivary glands in persons over 40 years of age^{13,50}. Chomette *et al.* report that the onset of MC according to age is variable and may occur between the 2nd and 8th decades of life⁶, in agreement with our study, in which onset ranged from the 2nd to 9th decades of life. Villavicencio *et al.* report onset from the 4th to 6th decades of life⁴⁸, and Rapidis *et al.* report 3rd to 9th decades of life¹⁷. Average age in all the aforementioned studies was the 6th decade of life, thus, average age of onset is reported as 52.2 years by Chomette *et al.*⁶; 54.3 years by Villavicencio *et al.*⁴⁸, and 56.7 years by Rapidis *et al.*¹⁷. These values are similar to the average age found in our study, which was 45.78 years. It is worth noting that this study found 8 cases of patients aged 19 years or under over the 10-year study period (0.8 cases per year), similar to findings reported by Techavichit *et al.* of 14 cases over a period of 15 years (0.9 cases per year) in patients aged 19 years or under⁵¹.

Villavicencio *et al.* report that the clinical size of the primary tumor varies according to the anatomical site affected; with median size 8 cm (4 to 10 cm) in submaxillary gland and 3 cm (1 to 5 cm) in minor salivary glands⁴⁸. Rapidis *et al.* found no statistically significant difference between tumor size according to site¹⁷. Katabi *et al.* report that tumor size was 0.5 to 9 cm, with an average value of 1.77 cm²⁹. In our study, the average size was 4.67 cm.

MC is a neoplasm that usually affects major salivary glands, although 10% can arise in minor or accessory salivary glands in the head and neck area²⁴, including maxillary sinus, nasopharynx, nasal cavity, oropharynx, larynx and trachea. Our study was consistent with this observation, finding 74.51% of the cases in parotid gland, 13.73% in submaxillary gland and 11.76% in minor glands. Ellis *et al.* report that 74.5% of neoplasms of the salivary glands in general are found in the parotid gland², with a percentage identical to the one found in our study. The location of MC in our study was also consistent with Villavicencio *et al.* who reported 74.5% in major salivary glands (32 cases in parotid and 3 cases in submaxillary gland)⁴⁸; Védrine *et al.*, who reported 18 cases, of

which 77.78% (14 cases) were in parotid gland, 11.11% (2 cases) in submaxillary gland and 11.11% (2 cases) in minor salivary glands⁷; Schwarz *et al.* who reported 60% (24 cases) in parotid gland, 10% (4 cases) in submandibular gland and 30% (12 cases) in minor glands⁴⁹, and Rapidis *et al.* who reported 18 cases, of which 66.6% (12 cases) were in major salivary glands (10 in parotid and 2 in submaxillary)¹⁷. Regarding location in minor salivary glands, Triantafillidou *et al.* report 56.25% in palate⁴⁰, while in our study, 100% of the minor salivary gland cases were located in the palate.

Signs and symptoms are varied, with none appearing as characteristic or pathognomonic, but the most outstanding in our study was pain, in agreement with Villavicencio *et al.*, who report pain in 55.3% of their 47 cases⁴⁸. It is worth noting that it is statistically significant ($p=0.038$) that most patients do not report paresthesia as a symptom at the time of the initial clinical examination.

Regarding the clinical stage of MC, Schwarz *et al.* report declining percentages for increasing stages, with 40% (16 cases) Type I, 30% (12 cases) Type II, 15% (6 cases) Type III and 15% (6 cases) type IV⁴⁹. In our study, the highest number of cases was found for the last stage, IV (16 cases), followed by stage II (15 cases).

In most epidemiological studies presenting data on the histological grade of the disease, the distribution of the number of MC cases generally declines as the level of histologic grade rises, i.e. there is an inverse relationship. Rapidis *et al.* report a decline according to histological grade, with 9 tumors classified as low grade, 5 as intermediate grade and 4 as high grade¹⁷; Katabi *et al.* report 90.38% (47 cases) low grade, 3.85% (2 cases) intermediate grade and 5.77% (3 cases) high grade²⁹; Védrine *et al.* report 68.75% (11 cases) low grade, 18.75% (3 cases) intermediate grade and 12.5% (2 cases) high grade⁷, and Schwarz *et al.* report 67.5% (27 cases) low grade, 7.5% (3 cases) intermediate grade and 25% (10 cases) high grade⁴⁹. Our study found equal numbers of cases for low grade and high grade with 39.22% (20 cases) each, and 21.56% (11 cases) intermediate grade. This higher percentage of cases with high histological grades may be due to the health culture in the Peruvian population, since people tend to consult a professional only when the disease is at an advanced stage.

Treatment is fairly well established, with most papers reporting surgical treatment and adjuvant radiation therapy, similarly to our casuistic, which shows that 41.18% was treated thus, which depends on the histologic grade. This is also reflected by follow-up case research such as Chen *et al.*, which follows a series of 61 cases, all of which were treated with surgery and postoperative radiation, for over 10 years⁵², and other papers which report casuistic of surgical treatment only, such as Rapidis *et al.*, who treated 9 cases of parotid gland tumors with superficial or total parotidectomy, all with radical dissection of neck or suprahyoid dissection,

with one parotid gland case being treated with hemimandibulectomy and suprahyoid dissection¹⁷. Based on the abovementioned findings, other studies were conducted which, in addition to the epidemiological contribution regarding this salivary gland disease, present the respective patient follow-up analyses for survival.

It is concluded that the epidemiology regarding age and gender of the 51 cases analyzed was in the same range as other studies, and that most cases were located in major salivary glands, in agreement with reports on other populations. Other characteristics showed a homogeneous distribution.

Correspondence

Dr. Janet-Ofelia Guevara-Canales
Av. Julio Bayletti 620 San Borja, Lima-41,
Lima, Peru.
janetguevara7@hotmail.com

REFERENCES

- Speight PM, Barrett AW. Salivary gland tumours. *Oral Dis* 2002; 8:229-240.
- Ellis GL, Auclair PL. Atlas of tumor pathology: Tumors of the major salivary glands. Washington DC, USA: Armed Forces Institute of Pathology (AFIP), 2008.
- Luna MA. Salivary mucoepidermoid carcinoma: revisited. *Adv Anat Pathol* 2006; 13:293-307.
- Ozawa H, Tomita T, Sakamoto K, Tagawa T, Fujii R, Kanzaki S, Ogawa K, Kameyama K, et al. Mucoepidermoid carcinoma of the head and neck: clinical analysis of 43 patients. *Jpn J Clin Oncol* 2008; 38:414-418.
- Stewart FW, Foote FW, Becker WF. Muco-epidermoid tumors of salivary glands. *Ann Surg* 1945; 122:820-844.
- Chomette G, Auriol M, Tereau Y, Vaillant JM. Mucoepidermoid tumors of minor salivary glands. Clinical and pathologic correlations. *Histoencytologic and ultrastructural studies. Ann Pathol* 1982; 2:29-40.
- Védrine PO, Coffinet L, Temam S, Montagne K, Lapeyre M, Oberlin O, Orbach D, Simon C, et al. Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms. *Head Neck* 2006; 28:827-833.
- Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head Neck Surg* 1986; 8: 177-184.
- World Health Organization. Classification of tumours. Pathology and genetics of head and neck tumours. Lyon, France: IARC Press, 2005.
- Copelli C, Bianchi B, Ferrari S, Ferri A, Sesenna E. Malignant tumors of intraoral minor salivary glands. *Oral Oncol* 2008; 44:658-663.
- Chou C, Zhu G, Luo M, Xue G. Carcinoma of the minor salivary glands: results of surgery and combined therapy. *J Oral Maxillofac Surg* 1996; 54:448-453.
- Auclair PL, Ellis GL. Mucoepidermoid carcinoma. In: Ellis GL, Auclair PL, Gnepp DR, editors: *Surgical pathology of the salivary glands*. Philadelphia, USA: W.B. Saunders, 1991:269-298.
- Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, Fahmy A, Bodian C, Urken ML, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. *Am J Surg Pathol* 2001; 25:835-845.
- Browand BC, Waldron CA. Central mucoepidermoid tumors of the jaws. Report of nine cases and review of the literature. *Oral Surg Oral Med Oral Pathol* 1975; 40:631-643.
- Raspall G. Glándulas Salivales. In: Dias H, editor: *Cirugía Maxilofacial Patología quirúrgica de la cara, boca, cabeza y cuello*. Madrid, España: Editorial Médica Panamericana, 1997:439.
- Myer C, Cotton RT. Salivary gland disease in children: a review. Part 1: Acquired non-neoplastic disease. *Clin Pediatr (Phila)* 1986; 25:314-322.
- Rapidis AD, Givalos N, Gakiopoulou H, Stavrianos SD, Faratzis G, Lagogiannis GA, Katsilieris I, Patsouris E. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. *Oral Oncol* 2007; 43:130-136.
- Kokemueller H, Brueggemann N, Swennen G, Eckardt A. Mucoepidermoid carcinoma of the salivary glands—clinical review of 42 cases. *Oral Oncol* 2005; 41:3-10.
- Pires FR, Pringle GA, de Almeida OP, Chen SY. Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. *Oral Oncol* 2007;43:463-470.
- Spiro RH, Huvos AG, Berk R, Strong EW. Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367 cases. *Am J Surg* 1978; 136:461-468.
- Ellis GL, Auclair PL, Gnepp DR. *Surgical pathology of the salivary glands*. Philadelphia, USA: W.B. Saunders;1991.

22. Allon I, Vered M, Buchner A, Dayan D. Stromal differences in salivary gland tumors of a common histopathogenesis but with different biological behavior: a study with picrosirius red and polarizing microscopy. *Acta Histochem* 2006; 108:259-264.
23. Dardick I. Histogenesis and morphogenesis of salivary glands neoplasms. In: Ellis GL, Auclair PL, Gnepp DR, editors: *Surgical pathology of the salivary glands*. Philadelphia, USA: W.B. Saunders, 1991:108.
24. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. *Cancer* 1992; 69:2021-2030.
25. Ellis GL, Auclair PL. *Atlas of tumor pathology: Tumors of the major salivary glands*. Washington DC, USA: Armed Forces Institute of Pathology (AFIP), 1996:173.
26. Barnes EL, Eveson JW AP, Reichart P, Sidransky D. World Health Organization. *Classification of tumours. Pathology and genetics of head and neck tumours*. Lyon, France: IARC Press, 2005.
27. Myer C, Cotton RT. Salivary gland disease in children: a review. Part 2: Congenital lesions and neoplastic disease. *Clin Pediatr (Phila)* 1986; 25:353-357.
28. Herd MK, Murugaraj V, Ghataura SS, Brennan PA, Anand R. Low-grade mucoepidermoid carcinoma of the palate-a previously unreported case of metastasis to the liver. *J Oral Maxillofac Surg* 2012; 70:2343-2346.
29. Katabi N, Ghossein R, Ali S, Dogan S, Klimstra D, Ganly I. Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading. *Histopathology* 2014; 65:793-804.
30. Hosokawa Y, Shirato H, Kagei K, Hashimoto S, Nishioka T, Tei K, Ono M, Ohmori K, et al. Role of radiotherapy for mucoepidermoid carcinoma of salivary gland. *Oral Oncol* 1999;35:105-111.
31. Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. *Otolaryngol Head Neck Surg* 1986; 95:165-170.
32. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. *Arch Otolaryngol Head Neck Surg* 1990; 116:290-293.
33. Leverstein H, van der Wal JE, Tiwari RM, Tobi H, van der Waal I, Mehta DM, Snow GB. Malignant epithelial parotid gland tumours: analysis and results in 65 previously untreated patients. *Br J Surg* 1998; 85:1267-1272.
34. Harrison LB, Armstrong JG, Spiro RH, Fass DE, Strong EW. Postoperative radiation therapy for major salivary gland malignancies. *J Surg Oncol* 1990; 45:52-55.
35. Hocwald E, Korkmaz H, Yoo GH, Adsay V, Shibuya TY, Abrams J, Jacobs JR. Prognostic factors in major salivary gland cancer. *Laryngoscope* 2001; 111:1434-149.
36. Renehan AG, Gleave EN, Slevin NJ, McGurk M. Clinicopathological and treatment-related factors influencing survival in parotid cancer. *Br J Cancer* 1999; 80:1296-1300.
37. Slevin N, Frankenthaler R. The role of radiotherapy in the management of salivary gland cancer. In: McGurk M, Renehan A, editors: *Controversies in the management of salivary gland disease*. Oxford, USA: Oxford University Press, 2001:163-172.
38. Frankenthaler RA, Luna MA, Lee SS, Ang KK, Byers RM, Guillaumondegui OM, Wolf P, Goepfert H. Prognostic variables in parotid gland cancer. *Arch Otolaryngol Head Neck Surg* 1991; 117:1251-1256.
39. McHugh CH, Roberts DB, El-Naggar AK, Hanna EY, Garden AS, Kies MS, Weber RS, Kupferman ME. Prognostic factors in mucoepidermoid carcinoma of the salivary glands. *Cancer* 2012; 118:3928-3936.
40. Triantafyllidou K, Dimitrakopoulos J, Iordanidis F, Koufogiannis D. Mucoepidermoid carcinoma of minor salivary glands: a clinical study of 16 cases and review of the literature. *Oral Dis* 2006; 12:364-370.
41. Cheuk W, Chan JK. Advances in salivary gland pathology. *Histopathology* 2007; 51:1-20.
42. Yih WY, Kratochvil FJ, Stewart JC. Intraoral minor salivary gland neoplasms: review of 213 cases. *J Oral Maxillofac Surg* 2005; 63:805-810.
43. Goode RK, Auclair PL, Barnes GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. *Cancer* 1998; 82:1217-1224.
44. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA. Stage as major long term outcome predictor in minor salivary gland carcinoma. *Cancer* 2000; 89:1195-1204.
45. Miyabe S, Okabe M, Nagatsuka H, Hasegawa Y, Inagaki A, Ijichi K, Nagai N, Eimoto T, et al. Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. *J Oral Maxillofac Surg* 2009; 67:1432-1441.
46. Spiro RH, Armstrong J, Harrison L, Geller NL, Lin SY, Strong EW. Carcinoma of major salivary glands. Recent trends. *Arch Otolaryngol Head Neck Surg* 1989; 115:316-321.
47. Kane WJ, McCaffrey TV, Olsen KD, Lewis JE. Primary parotid malignancies. A clinical and pathologic review. *Arch Otolaryngol Head Neck Surg* 1991; 117:307-315.
48. Villavicencio-Ayala B, Reséndiz-Colosia JA, Labastida-Almendaro S, Torres-Núñez MG, Peña-Torres LM, Gallegos-Hernández JF. Prognostic factors in head and neck mucoepidermoid carcinoma. *Cir Cir* 2008; 76:109-117.
49. Schwarz S, Stiegler C, Müller M, Ettl T, Brockhoff G, Zenk J, Agaimy A. Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. *Histopathology* 2011; 58:557-570.
50. Boahene DK, Olsen KD, Lewis JE, Pinheiro AD, Pankratz VS, Bagniewski SM. Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience. *Arch Otolaryngol Head Neck Surg* 2004; 130:849-856.
51. Techavichit P, Hicks MJ, López-Terrada DH, Quintanilla NM, Guillerman RP, Sarabia SF, Sayeed H, Nuchtern JG et al. Mucoepidermoid carcinoma in children: a single institutional experience. *Pediatr Blood Cancer* 2016; 63:27-31.
52. Chen AM, Lau VH, Farwell DG, Luu Q, Donald PJ. Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome. *Laryngoscope* 2013;123:3049-3055.